---

---

What is an advisory committee?

Advisory committees provide independent expert advice to the FDA on broad scientific topics or on certain products to help the agency make sound decisions based on the available science. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so. Please see, "Advisory Committees Give FDA Critical Advice and the Public a Voice," for more information.

Agenda

On June 26, 2024, the Center for Tobacco Product's Tobacco Products Scientific Advisory Committee (TPSAC) will convene for one open session, during which the committee will discuss the renewal of a risk modification order, submitted by Swedish Match USA, Inc. for General Snus products. Additional discussion about the conceptualization and measurement of consumer understanding within the broader modified risk tobacco products program will also occur. The meeting will be open to the public.

---

Meeting Materials

FDA intends to make background material available to the public no later than two business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s website after the meeting. Materials for this meeting will be available on FDA’s Swedish Match Modified Risk Tobacco Products page.

---

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. 

• Written submissions may be made to the contact person on or before June 20, 2024. 
• Oral presentations from the public will be scheduled between approximately 1:30 p.m. and 2:30 p.m. ET on June 26, 2024. 

Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement describing the general nature of the evidence or arguments they wish to present and the names and email addresses of proposed participants, whether they would like to present online or in person, on or before June 11, 2024, by 5 p.m. ET. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. Similarly, room for interested persons to participate in-person may be limited. If the number of registrants requesting to speak in-person during the open public hearing is greater than can be reasonably accommodated in the venue for the in-person portion of the advisory committee meeting, FDA may conduct a lottery to determine the speakers who will be invited to participate in person. The contact person will notify interested persons regarding their request to speak by June 12, 2024.

---

Contact Information

• CAPT Serina Hunter-Thomas, 240-402-5771, e-mail: serina.hunter-thomas@fda.hhs.gov 
• FDA Advisory Committee Information Line: 1-800-741-8138 (301-443-0572 in the Washington, DC area) Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the meetings main page or call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. 

If you require special accommodations due to a disability, please contact Serina Hunter-Thomas at least 7 days in advance of the meeting.

Information regarding ground transportation, airport information, lodging, driving directions, visitor parking, and security can be accessed at the public meetings at White Oak main page.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

---